The performance of companies tied to flagship drugs like Viagra presents a challenging investment picture. While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial profits , the expiry in key regions has introduced significant uncertainty . Investors are now assessing the effect of rival medications , dim